FDA Approves Ibrutinib for Paediatric Patients with Chronic Graft Versus Host Disease, Including a New Oral Suspension
Evidence for efficacy is based on the results from the iMAGINE study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1552 results
FDA Approves Durvalumab for Locally Advanced or Metastatic Biliary Tract Cancer
Evidence for efficacy is based on the results from the TOPAZ-1 study
FDA Approves Pemigatinib for Relapsed or Refractory Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
Evidence for efficacy was evaluated in FIGHT-203 study
Utility of Serial ctDNA in Guiding Anti-EGFR Rechallenge in Metastatic Colorectal Cancer
Paired tissue and ctDNA sequencing identified multiple novel mutations, copy gains, and fusions that frequently co-occur as subclonal alterations
EMA Recommends Granting a Marketing Authorisation for Hybrid Thalidomide
Thalidomide Lipomed is intended for the treatment of multiple myeloma
Sacituzumab Govitecan Demonstrates Significant Improvement in Survival in Heavily Pretreated, Locally Recurrent Inoperable, or Metastatic HR-positive, HER2-negative Breast Cancer
Primary results of the TROPiCS-02 study
FDA Grants Accelerated Approval to fam-Trastuzumab Deruxtecan-nxki for HER2-Mutated NSCLC
FDA also approved companion diagnostics for selection of patients
EMA Recommends Granting a Marketing Authorisation for Celdoxome Pegylated Liposomal
It is a hybrid medicine of Adriamycin, but available in a pegylated liposomal formulation
Long-Term Outcomes Suggest a Sustained Clinical Benefit to Metastasis-Directed Treatment Over Observation in Oligometastatic Castration-Sensitive Prostate Cancer
Long-term follow-up findings from STOMP and ORIOLE and analysis of genomic predictors of response
Associations Between Genomic Features and Response to Neoadjuvant Treatment in a Large Cohort of Patients with Rectal Cancer
A comprehensive analysis highlights clinically relevant associations between genomic, transcriptomic features, immunologic profiles and treatment outcomes
FDA Approves Capmatinib for Metastatic NSCLC
Conversion from accelerated to regular approval was based on data from additional patients in the GEOMETRY mono-1 study
Rapid, Robust and Durable Antitumour Activity of Pralsetinib in Patients with Different RET Fusion Positive Solid Tumours
ARROW validates RET as a tissue-agnostic target